

14 NOVEMBER 2022 OLD BILLINGSGATE, LONDON 6PM-12 MIDNIGHT GMT 16 CATEGORIES
18 COUNTRIES
5 REGIONS
150+ FINALISTS

# THE EUROPEAN LIFESTARS AWARDS

The annual, European Lifestars Awards (ELAs) bring together hundreds of European life science leaders, investors, partners and deal makers. It is a celebration of the success stories, breakthroughs, transactions and transformational deals and the people, teams and organisations that have played a critical role in the advancement of the industry over a 12 month period.

We are dedicated to helping our industry **Celebrate** with purpose<sup>™</sup>

The **European Lifestars Awards** are instrumental in highlighting the incredible work being carried out across the life science value chain. They are the only life science industry awards ceremony to celebrate not just the companies and individuals, but the countries and regions that they represent.

**16 awards** will be contested by **150+ finalists** representing **18 countries** from the **5 regions** of Europe. They will be joined by hundreds of their support network at this year's inperson ceremony.

One region will also be crowned Region Champion on the night.

The prestigious awards ceremony will be held exclusively live on the 14th November 2022 and will combine a champagne reception, Charity silent auction, live evening entertainment, gala dinner and a celebrity compère who will announce and present Winners alongside executives from our esteemed Awards partners.

The ELAs are where the great and the good of the sector recognise and celebrate their collective achievements.





Coulter:Partners

Kempen

COVINGTON

Jefferies









## categories have been chosen to help shine a light on the breadth and depth of breakthroughs, transactions and deal making that have taken place during the 12-month qualifying period.

The categories acknowledge and celebrate the achievements of fledgling life science start-ups all the way through to Pharma giants, and everyone in between.

There will be an individual Winner and a Highly Commended in each category.



2. Series A Finance Raise of the Year

3. Series B Finance Raise of the Year

4. Series C (& beyond) Finance Raise of the Year

5. IPO of the Year

6. Post-IPO Equity Raise of the Year

7. Venture Capital Firm of the Year

8. Deal of the Year (<€500m)

9. Deal of the Year (>€500m)

10. M&A Deal of the Year

11. Pharma BD Team of the Year

12. Biotech Company of the Year

13. Medtech Company of the Year

14. Healthtech Company of the Year

15. Private Company CEO of the Year

16. Public Company CEO of the Year



### SHORES SURGIBLE SURGIB SU

The European Lifestars Awards (ELAs) are the only life science industry awards ceremony to celebrate the regional industry demographic of the finalists, in addition to the companies and individuals contesting the categories.

The 18 countries eligible to take part will be allocated a place in 1 of 5 regions. Each region will contest the 2022 Region Champion Award at the end of the formal ceremony.

Each region is allocated countries that have the ability to support finalists in each of the 16 Award categories and in all cases share a similar industry demographic. Each region will have 30 finalists on the night from its constituent countries.

Countries are not guaranteed an equal number of finalists, the strength of the individual finalist roster will dictate the geographical makeup of their region group.

The finishing position of each individual finalist, and hence their representative region will carry a points scoring and it is these points that, tallied throughout the evening and, combined with the public vote, will determine the 2022 Region Champion.

## BENELUX



## DACH



## **MEDITERRANEAN**



## **NORDICS**



## **UK & IRELAND**



BELGIUM | LUXEMBOURG THE NETHERLANDS

GERMANY | AUSTRIA SWITZERLAND

FRANCE | ISRAEL | ITALY
SPAIN | PORTUGAL

DENMARK | FINLAND | ICELAND | NORWAY | SWEDEN

UNITED KINGDOM IRELAND

## **AWARDS PROCESS**

## 1JANUARY - NOMINATIONS OPEN & JUDGING COMMITTEE FORMED

- Entrants are invited to complete a short online nomination form, including a 400-word supporting document in a maximum of 2 categories.
- The international judging committee is formed from key industry stakeholders and corporate partners.
- The committee are invited to provide their own nominations to accompany solicited entries.

## **1OCTOBER - NOMINATIONS CLOSE & COMMITTEE CONVENE**

- Solicited and judging committee nominations are closed to entry, collated and validated.
- Committee engage in validation of entrants creating a finalist roster that represents each of the five regions.

## 15 OCTOBER - FINALISTS INFORMED AND ROSTER RELEASED

- The 150+ finalist roster is released publicly via traditional and social media channels.

## 1 NOVEMBER - JUDGING COMMITTEE FINAL VOTING

- Committee engage in the official round of voting providing scores for each finalist
- The scores are used to order the finishing positions of each finalist in their categories.

## 9 NOVEMBER - PUBLIC VOTE IS OPEN FOR A PERIOD OF 72HRS

 A weighting of 20% will be allocated to the public vote outcome. These and the judges scores will be combined to produce the Region Champion.

## 14 NOVEMBER - AWARDS CEREMONY HELD LIVE

- Finalists, judges, sponsors and the wider global life science industry attend the 2022 awards ceremony live from 6pm GMT at Old Billingsgate, London.

The international judging faculty of the 2022 European Lifestars
Awards are chosen for their wealth of industry experience and strength of their cross-border knowledge.

They are selected from a geographically diverse pool of leading investors, pharma, global advisory, law firms, professional and financial services, contract services, PR and IR Firms and key stakeholders.

Members of the faculty participate in two rounds of submission review and voting to generate this year's finalists and to select the winners.

## 1JANUARY-1OCTOBER

- Judges select their categories for review and submit their own entries across their regions.

## 1-15 OCTOBER

- Committee engage in a round of initial validation of entrants creating a finalist roster that represents each of the five regions.

## FROM 1 NOVEMBER

- Committee engage in an officiall round of voting providing scores for each finalist.

If you would like to enquire about joining the judging faculty email lifestars@lsxleaders.com







## SEED FINANCE RAISE OF THE YEAR



This award recognises a company that has successfully completed a significant, impactful or transformational private fundraise at Seed-Stage level.

It is open to private European life science companies only.

This award recognises a company that has successfully completed a significant, impactful or transformational private fundraise at Series A level.

It is open to private European life science companies only.

## **Qualifying Criteria**

- Must be a fundraise by a private company
- Must have raised the funds in the period between 1 September 2021 and 1 October 2022
- · Must be a company with European headquarters

## **Judges Will Be Paying Particular Attention To:**

- · Amount of funds raised
- Process / speed / allocation fulfilment of securing significant new funds
- Level / reputation of investors attracted
- · Post-finance allocation / use of proceeds
- · Level of value creation / value realisation from raise
- Company research / technology focus and novelty / meeting unmet need

## **Qualifying Criteria**

- · Must be a fundraise by a private company
- Must have raised the funds in the period between 1 September 2021 and 1 October 2022
- Must be a company with European headquarters

## **Judges Will Be Paying Particular Attention To:**

- Amount of funds raised
- Process / speed / allocation fulfilment of securing significant new funds
- Level / reputation of investors attracted
- Post-finance allocation / use of proceeds
- Level of value creation / value realisation from raise
- Company research / technology focus and novelty / meeting unmet need

**SUBMIT ENTRY** 







This award recognises a company that has successfully completed a significant, impactful or transformational private fundraise at Series B level.

It is open to private European life science companies only.

**Qualifying Criteria** 

- · Must be a fundraise by a private company
- Must have raised the funds in the period between 1 September 2021 and 1 October 2022
- · Must be a company with European headquarters

## **Judges Will Be Paying Particular Attention To:**

- · Amount of funds raised
- Process / speed / allocation fulfilment of securing significant new funds
- Level / reputation of investors attracted / reputation of investors reinvesting
- · Post-finance allocation / use of proceeds
- · Level of value creation / value realisation from raise

SUBMIT ENTRY

This award recognises a company that has successfully completed a significant, impactful or transformational private fundraise at Series C or beyond level.

It is open to private European life science companies only.

## **Qualifying Criteria**

- · Must be a fundraise by a private company
- Must have raised the funds in the period between 1 September 2021 and 1 October 2022
- · Must be a company with European headquarters

## **Judges Will Be Paying Particular Attention To:**

- · Amount of funds raised
- Process / speed / allocation fulfilment of securing significant new funds
- Level / reputation of investors attracted / reputation of investors reinvesting
- Post-finance allocation / use of proceeds
- Level of value creation / value realisation from raise







This award recognises a company that has successfully completed a significant, impactful or transformational IPO on any exchange.

It is open to public European life science companies only.

This award recognises a company that has successfully completed a significant, impactful or transformational secondary placement or follow-on equity raise (not debt) on any exchange. It is open to public European life science companies only.

## **HOSTED BY:**



## **Qualifying Criteria**

- · Must be a public company
- Must have raised the funds in the period between 1 September 2021 and 1 October 2022
- Must be a company with a European headquarters
- Must be an IPO (primary, up-listing or dual-listing) NOT a secondary placement or follow-on

## **Judges Will Be Paying Particular Attention To:**

- · Amount of funds raised
- Process / speed / allocation fulfilment of securing significant new funds
- · Level / reputation of new investor(s) attracted
- Post-finance allocation / use of proceeds
- · Level of value creation / value realisation from raise


**SUBMIT ENTRY** 

## **Qualifying Criteria**

- Must be a public company
- Must have raised the funds in the period between 1 September 2021 and 1 October 2022
- Must be a company with a European headquarters
- Raise must be a secondary placement or follow-on NOT an IPO, uplisting or dual-listing

## **Judges Will Be Paying Particular Attention To:**

- · Amount and type of funds raised
- Process / speed / allocation fulfilment of securing significant new funds
- Level / reputation of investor(s) attracted
- Post-finance allocation / use of proceeds
- Level of value creation / value realisation from raise





## VENTURE CAPITAL FIRM OF THE YEAR



This award recognises a European life science company that has successfully completed a significant, impactful or transformational venture debt or growth loan financing.

It is open to private and public European life science companies.

TThis award recognises the teams and organisations who have executed a truly transformational and high value creating deal for both the company and the wider industry. The deal could be a licensing agreement, codevelopment or a creative alliance or partnership that unlocks significant value.

## **HOSTED BY:**



## **Qualifying Criteria**

- · Open to venture capital firms only
- Firm must have more than 20% portfolio holdings in healthcare and/ or life sciences companies
- Period to be judged review is between 1 September 2021 and 1 October 2022
- · Firms must have headquarters in Europe

## **Judges Will Be Paying Particular Attention To:**

- · Evidence of innovative company creation and deal-making strategies
- · Volume of investments made in the qualifying timeline
- · Number of lead investments made
- · Number / quality of successful exits
- · Number / value of new funds raised
- · Fund performance and returns to LPs

**SUBMIT ENTRY** 

## **HOSTED BY:**



## **Qualifying Criteria**

- Deal size must be less than €500m
- The lead company must be a European Life Science company
- Open to private or public companies WITH peers, pharma, commercial leaders or big tech
- Deal can be either a licensing deal, single asset acquisition or collaborative agreement involving a particular drug, project or group of drugs/projects
- · A license, partnership or alliance between companies NOT M&A
- Deal to have completed in the period between 1 September 2021 and 1 October 2022

## **Judges Will Be Paying Particular Attention To:**

- · Uniqueness or novelty of deal strategy / terms and structure
- Level of value creation / size of deal (upfront, milestone and total value)
- Strength of partner / partnership and deal teams
- Potential game / industry changing implications within next
   12-months
- Post-deal performance







This award recognises the teams and organisations who have executed a truly transformational and high value creating deal for both the company and the wider industry. The deal could be a licensing agreement, co-development or a creative alliance or partnership that unlocks significant value.

This award recognises the teams and organisations who have executed a truly transformational and high value M&A deal for both the company and the wider industry.

**HOSTED BY:** 

## Baker McKenzie.

## **Qualifying Criteria**

- · Deal size must be equal to or greater than €500m
- The lead company must be a European Life Science company
- Open to private or public companies WITH pharma, commercial leaders or big tech
- Deal can be either a licensing deal, single asset acquisition or collaborative agreement involving a particular drug, project or group of drugs/projects
- · A license, partnership or alliance between companies NOT M&A
- Deal to have completed in the period between 1 September 2021 and 1 October 2022

## **Judges Will Be Paying Particular Attention To:**

- · Uniqueness or novelty of deal strategy / terms and structure
- · Level of value creation / size of deal (upfront, milestone and total value)
- · Strength of partner / partnership and deal teams
- · Potential game / industry changing implications within next 12-months
- Post-deal performance

**SUBMIT ENTRY** 

## **HOSTED BY:**

## Baker McKenzie.


## **Qualifying Criteria**

- The lead company must be a European Life Science company
- Open to private, public companies, pharma, commercial leaders or big tech
- Deal must be an M&A (including asset business unit) deal NOT a license, partnership or alliance
- Deal to have completed in the period between 1 September 2021 and 1 October 2022

## **Judges Will Be Paying Particular Attention To:**

- · Uniqueness or novelty of deal strategy / terms and structure
- · Level of value creation / size of deal
- Strength of acquirers existing pipeline / synergy with existing portfolio
- Potential game / industry changing implications within next
   12-months
- Post-deal performance





## PHARMA BD TEAM OF THE YEAR



## BIOTECH OF THE YEAR

This award recognises the business development team from a pharma or large cap biotech company that has excelled in sourcing, executing and delivering extraordinary and transformational deals that created significant value for

consumers, company and shareholders.

**Qualifying Criteria** 

- Open to all pharma companies and large cap large cap biotech companies with a market capitalisation that is \$10bn or above.
- Open to all business development teams or cross-company teams on a specific deal/project
- Criteria relates to the period between 1 September 2021 and 1 October 2022

## **Judges Will Be Paying Particular Attention To:**

- · Quality and volume of deals completed
- · Achievement of milestones and goals and the overcoming of obstacles
- · Uniqueness or novelty of deal strategies/terms and structure
- · Strength of team leadership and culture
- · How alignment across parties was achieved

**SUBMIT ENTRY** 

excellence in strategy, process, focus and execution to create significant value for patients, investors, employees and the broader life science community.

This award recognises a European Biotech (drug discovery, pre-clinical,

clinical, OTM therapeutic) company that has demonstrated a superior

## **HOSTED BY:**



## **Qualifying Criteria**

- Open to all Biotech therapeutic companies with European Headquarters
- Open to all Biotech companies companies with a market capitalisation that is \$10bn or less.
- Submission relates to activities achieved in the period between 1 September 2021 and 1 October 2022

## **Judges Will Be Paying Particular Attention To:**

- Targeting of unmet medical need / use of innovative approaches to pipeline development
- Pipeline progress through drug discovery / pre-clinical / clinical stages / market approval
- Closure of fundraises and strategic financing rounds
- Key stages of strategic development / partnerships
- Implementation of new technologies, processes for strategic advantage





## MEDTECH OF THE YEAR



This award recognises a European Medtech (device, surgical, diagnostic) company that has demonstrated superior excellence in strategy, process, focus and execution to create significant value for patients, investors, employees and the broader life science community.

This award recognises a European Healthtech (digital health, digital therapeutics, databases, applications and wearables) company that has demonstrated a superior excellence in strategy, process, focus and execution to create significant value for consumer, patients, investors, employees and the broader life science community.

**HOSTED BY:** 



## **Qualifying Criteria**

- Open to all Medtech/Medical Device companies with European Headquarters
- Open to all Medtech/Medical Device companies with a market capitalisation that is \$10bn or less.
- Submission relates to activities achieved in the period between 1 September 2021 and 1 October 2022

## **Judges Will Be Paying Particular Attention To:**

- Targeting of unmet medical need / use of innovative approaches to product development
- Pipeline progress through in-development / clinical stages / market approval
- · Closure of fundraises and strategic financing rounds
- Key stages of strategic development / partnerships
- Implementation of new technologies, processes for strategic advantage

**SUBMIT ENTRY** 

## **HOSTED BY:**

## COVINGTON

## **Qualifying Criteria**

- Open to all Healthtech companies with European Headquarters
- Open to all Healthtech companies companies with a market capitalisation that is \$10bn or less.
- Submission relates to activities achieved in the period between 1
   September 2021 and 1 October 2022

## **Judges Will Be Paying Particular Attention To:**

- Targeting of unmet medical need / use of innovative approaches to product development
- Pipeline progress through in-development / clinical stages / market approval
- · Closure of fundraises and strategic financing rounds
- Key stages of strategic development / partnerships
- Implementation of new technologies, processes for strategic advantage



## PRIVATE COMPANY CEO OF THE YEAR



This award recognises a private company CEO that has demonstrated truly outstanding and exemplary leadership in their respective companies.

This award recognises a publicly-listed company CEO that has demonstrated truly outstanding and exemplary leadership in their respective companies.

### **HOSTED BY:**

## Coulter:Partners

## **Qualifying Criteria**

- · Open to CEOs of privately owned life science companies
- Period to be judged review is between 1 September 2021 and 1 October 2022

## **Judges Will Be Paying Particular Attention To:**

- · Career achievements and leadership qualities
- · How the has CEO created value for shareholders and investors
- · What the CEOs greatest achievements were in this period
- · Creation of new partnerships / leveraging existing partnerships
- What the CEO has done to influence and advance the wider life science industry

### **HOSTED BY:**

## **Jefferies**

## **Qualifying Criteria**

- · Open to CEOs of publicly-listed life science companies
- Period to be judged review is between 1 September 2021 and 1 October 2022


## **Judges Will Be Paying Particular Attention To:**

- · Career achievements and leadership qualities
- · How has the CEO created value for shareholders and investors
- · What the CEOs greatest achievements were in this period
- · Creation of new partnerships / leveraging existing partnerships
- What the CEO has done to influence and advance the wider life science industry

**SUBMIT ENTRY** 

**SUBMIT ENTRY** 

## AWADNC AWADNC



Nominate for free, but finalists must be available to attend and participate in the awards ceremony on November 14th, which requires the purchase of tickets. Inability to attend will void your application.

Please refer to Tickets page for full details and benefits.

Entrants must provide evidence - they should demonstrate the entry fits both the eligibility criteria and the required time frame. Nominations not fitting the criteria or not meeting the minimum entrance requirements will be voided.

Entry does not guarantee selection - all finalists will be informed personally as to their progress.

Confidentiality is key - only the ELA management team and judges are permitted to view the entries and supporting information.

Judges are recruited based on their experience - they give up much of their time to review the entries provided and are not paid for their role.

If you have any questions about your eligibility to join the ELAs please contact us at <a href="mailto:lifestars@lsxleaders.com">lifestars@lsxleaders.com</a>

## MHY ENTER THE AWARDS

Entering the European
Lifestars Awards offers you an
unrivalled opportunity to gain
acknowledgement and celebrate
the successes of your company, its
employees and the wider life science
industry.

It presents an opportunity to reward and inspire and spur you and your team on to greater heights.

- · Achieve peer recognition and gain external validation
- Become an awards winning business and raise company credibility
- Increase brand recognition and reputation through positive PR
- · Send a positive message to customers and prospects
- · Secure new investors and partners to grow your business
- Benchmark against your industry peers and competitors
- · Attract 'A' grade talent and raise your hiring stature
- Benefit from year round promotion and news flow
- Network with executives from the year's biggest success stories
- Surround yourself with a service support network that has helped this year's finalist roster

**SUBMIT AN ENTRY** 

# CORPORATE PARTNERSHIP

## The European Lifestars Awards

offers a number of unique ways to raise your company profile amongst the hundreds of executives attending the evening ceremony and the thousands of executives in our community that will see the pre- and post-event promotional campaign.

Opportunities for Co-Host, Regional, Hospitality and Category-level partners to promote their brand, align their company with industry excellence and entertain and network with clients and valued prospects:

## **CO-HOST PARTNER**

 The package for a company wishing to demonstrate industry-wide leadership

## **REGIONAL PARTNER**

The package for a company wishing to demonstrate its regional focus, experience and expertise.

## **HOSPITALITY PARTNER**

 The package for a company wishing to raise its company profile and educate an engaged audience.

.....

## **CATEGORY PARNER**

 The package for a company wishing to demonstrate its experience and expertise in a specific service offering.

......

Whatever your corporate message, strategy or marketing outreach programme, there is a package for you.

Details of each of the four packages can be found in the pages that follow, but to request a callback to discuss any of these options, click lifestars@lsxleaders.com

## O-HOST PARTNER

## **Co-host** partnership is

the highest level of partnership afforded at the European Lifestars Awards. Opportunities exist for one investment bank, one global advisory, one law firm, one exchange and one pharma at this level.

The package to demonstrate industry-wide leadership.

## **CORPORATE BRANDING LEVEL**

- Co-lead level branding on pre-event, on-thenight, and post-event website and marketing materials.
- Profile exclusivity at co-host level.
- · Double page advert in onsite ceremonial guide.

## **JUDGING FACULTY MEMBERSHIP**

 1 judging faculty member to nominate, review and score in each of the 5 regions and all categories.

## CATEGORY HOST AND WINNER PRESENTATION

- An executive to present the winner of one category during the live ceremony.
- · Corporate logo placement on award trophy.

## REGION CHAMPION CO-HOST AND WINNER PRESENTATION

Co-branding during presentation to regional winner.

### **ONSITE PRESENCE**

• A VIP table of 10 executives / clients with corporate branding.

INVESTMENT
LEVEL from £££££

## REGIONAL PARTNER

## Regional partnership

is the second
highest level
of partnership
afforded at
the European
Lifestars Awards.
Opportunities exist
for a maximum of
three co-hosts from
investment bank,
global advisory, law
firm, exchange or
pharma profiles.

## **CORPORATE BRANDING LEVEL**

- Secondary tier branding on pre-event, on-thenight, and post-event website and marketing materials..
- Co-branding of the 'region' finalists lanyards and table plans.
- Co-Branding of the presentation of the regional winners if your region wins.
- Single page advert in onsite ceremonial guide.

## **JUDGING FACULTY MEMBERSHIP**

 1 judging faculty member to nominate, review and score in each of the 5 regions and all categories.

## **CATEGORY HOST AND WINNER PRESENTATION**

- An executive to present the winner of one category during the live ceremony.
- · Corporate logo placement on award trophy.

.....

from ££££

## **ONSITE PRESENCE**

 A VIP table of 10 executives / clients with corporate branding.

# HOSPITALITY PAPTINED

Hospitality
partnership is the
second highest
level of partnership
afforded at
the European
Lifestars Awards.
Opportunities exist
for all profiles to
engage at this level.

The package for a company wishing to raise its company profile with an engaged c-suite audience.

## **CORPORATE BRANDING LEVEL**

- Second tier branding on pre-event, on-thenight, and post-event website and marketing materials..
- · Single page advert in onsite ceremonial guide..

## JUDGING FACULTY MEMBERSHIP

 1 judging faculty member to nominate, review and score in each of the 5 regions and all categories.

## **CATEGORY HOST AND WINNER PRESENTATION**

- An executive to present the winner of one category during the live ceremony.
- · Corporate logo placement on award trophy.

## **NETWORKING & ENTERTAINMENT HOST**

- Select the Charity, exclusive branding of Charity Silent Auction and evening entertainment.
- Co-branding during the pre-dinner champagne reception.

## **ONSITE PRESENCE**

 2 tickets for executives to attend the awards ceremony..

INVESTMENT
LEVEL from ££££

# CATEGORY PARTNER

## Award category partnership is the third highest level of partnership afforded at the European Lifestars Awards. Opportunities exist for all profiles to engage at this level.

The package for a company wishing to demonstrate its experience and expertise in a specific service offering.

## **CORPORATE BRANDING LEVEL**

- Third tier branding on pre-event, on-thenight, and post-event website and marketing materials..
- · Single page advert in onsite ceremonial guide.

## **JUDGING FACULTY MEMBERSHIP**

 1 judging faculty member to nominate, review and score in each of the 5 regions and all categories.

## **CATEGORY HOST AND WINNER PRESENTATION**

- An executive to present the winner of one category during the live ceremony.
- Corporate logo placement on award trophy.

## **ONSITE PRESENCE**

 2 tickets for executives to attend the awards ceremony.

## INVESTMENT LEVEL from £££

## REASONS TO PARTNER

## **INFLUENCE**

- Contribute to this year's nomination process by referring clients / peers
- Participate in the judging faculty nomination process, providing your own votes alongside the external solicited nomination process.
- Review this year's award submissions, validate the finalist roster and participate in a final voting round to select this year's winners and highly commended.
- Create a social buzz around this year's finalists and promote the individuals, companies, countries and regions to your network.

## **ENHANCE**

- Further elevate yourself as a key stakeholder in the industry and leverage your expertise to help determine this year's winners.
- Command a prominent place on 2021 official judging committee alongside peers and esteemed colleagues.
- Use the strength of the European Lifestars Awards brand and promotional machine to maximise yours and your company's exposure and PR on an international stage.

## **REAP**

- Network with executives from the year's biggest success stories.
- Join your industry's biggest night of celebrations and corporate achievement.
- Be part of the story that promote's the best your industry has to offer.

# MARDS WENUE

The prestigious ELA's will return as inperson in 2022 held at the prestigious Old Billingsgate, London venue.

In the heart of the City on the North bank of the River Thames, stands this striking historic building that is a remarkable part of London's heritage.

Old Billingsgate, a Victorian Grade II listed building was once a world famous fish market, and having undergone an industrial twist by architect Lord Richard Rogers, the building has taken on an amazing transformation, from the 19th century's largest fish market to London's premier event space, home of the 2022 European Lifestars Awards.





## **HELP WITH THE PROCESS?**

Get in touch with the awards team who would be happy to talk you through the process and offer some advice

## **NEIL DARKES**

+44 (0) 207 039 3401 lifestars@lsxleaders.com

www.europeanlifestarsawards.com